Skip to content

CRISPR Therapeutics AG

CRSP

CIK 0001674416

← back to feed
Revenue (TTM)
$4.1M
−90.6% YoY Q1 Apr 2026
Net Income (TTM)
−$573.92M
−58.8% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$6.43
−49.1% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-15,595.9%
Q1 Apr 2026
Net Margin
-13,984.3%
Q1 Apr 2026
Free Cash Flow (TTM)
−$48.78M
Q1 Apr 2026
Cash
$423.31M
Q1 Apr 2026
Total Debt
$585.47M
Q1 Apr 2026
Shares Outstanding
96.45M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings